The Peter Attia Drive cover image

#38 - Francisco Gonzalez-Lima, Ph.D.: Advancing Alzheimer’s disease treatment and prevention – is AD actually a vascular and metabolic disease?

The Peter Attia Drive

00:00

The Pros and Cons of the Methylene Blue Derivative

There was a company in Scotland that ran a compound LMTM and the trial which was announced results of this trial were announced about two years ago. The study basically took patients in early stages of dementia, randomized them to various interventions. But one of them was this agent, this LMTM, which they described as a methylene blue derivative.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app